Munster PN - Search Results

1

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.

Thurn KT, Thomas S, Moore A, Munster PN. Thurn KT, et al. Among authors: munster pn. Future Oncol. 2011 Feb;7(2):263-83. doi: 10.2217/fon.11.2. Future Oncol. 2011. PMID: 21345145 Free PMC article. Review.

2

Development of histone deacetylase inhibitors for cancer treatment.

Marchion D, Münster P. Marchion D, et al. Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. doi: 10.1586/14737140.7.4.583. Expert Rev Anticancer Ther. 2007. PMID: 17428177 Review.

3

Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.

Thomas S, Munster PN. Thomas S, et al. Among authors: munster pn. Cancer Lett. 2009 Aug 8;280(2):184-91. doi: 10.1016/j.canlet.2008.12.026. Epub 2009 Jan 30. Cancer Lett. 2009. PMID: 19185986 Review.

4

Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Munster P, et al. Clin Cancer Res. 2009 Apr 1;15(7):2488-96. doi: 10.1158/1078-0432.CCR-08-1930. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318486 Clinical Trial.

5

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. Munster PN, et al. Br J Cancer. 2009 Oct 6;101(7):1044-50. doi: 10.1038/sj.bjc.6605293. Epub 2009 Sep 8. Br J Cancer. 2009. PMID: 19738609 Free PMC article. Clinical Trial.

6

Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.

Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Thomas S, et al. Among authors: munster pn. Breast Cancer Res Treat. 2011 Nov;130(2):437-47. doi: 10.1007/s10549-011-1364-y. Epub 2011 Feb 5. Breast Cancer Res Treat. 2011. PMID: 21298336 Free PMC article.

7

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.

Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. Munster PN, et al. Br J Cancer. 2011 Jun 7;104(12):1828-35. doi: 10.1038/bjc.2011.156. Epub 2011 May 10. Br J Cancer. 2011. PMID: 21559012 Free PMC article. Clinical Trial.

8

Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.

Raha P, Thomas S, Munster PN. Raha P, et al. Among authors: munster pn. Epigenomics. 2011 Aug;3(4):451-70. doi: 10.2217/epi.11.72. Epigenomics. 2011. PMID: 22126205 Review.

9

Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. Munster PN, et al. J Clin Oncol. 2012 Feb 10;30(5):533-8. doi: 10.1200/JCO.2011.34.6890. Epub 2012 Jan 9. J Clin Oncol. 2012. PMID: 22231041 Free PMC article. Clinical Trial.

10

Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt.

Thomas S, Thurn KT, Raha P, Chen S, Munster PN. Thomas S, et al. Among authors: munster pn. PLoS One. 2013 Jul 9;8(7):e68973. doi: 10.1371/journal.pone.0068973. Print 2013. PLoS One. 2013. PMID: 23874830 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

167 results

Search Page

Filters